Search
Rein Therapeutics Inc
RNTXAdd to Watchlist
0.776USD
-0.015-1.92%
Close 07-27 16:00（ET）Quotes delayed by 15 min
21.76MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Rein Therapeutics Inc is 7.00, ranking 310 out of 386 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 10.00 and a low of 6.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.000
Target Price
+658.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Rein Therapeutics Inc
RNTX
3
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Rein Therapeutics Inc's price target?
Analysts forecast that Rein Therapeutics Inc's price target is USD 8.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 6.00.
How have Rein Therapeutics IncRNTX's recent earnings per share performed?
The market expectation was USD -0.19, while Rein Therapeutics IncRNTX's earnings per share (EPS) for the previous quarter was USD -1.09. EPS for the next quarter is expected at USD -0.17.
What is the analyst rating for Rein Therapeutics Inc?
Based on the ratings of Rein Therapeutics Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.